QuellTX Logo
t: 0207 096 9012
Quell Logo ×

Restoring the Balance With Regulatory T cell Therapies

Harnessing the suppressive capacity of Tregs to address immune dysfunction utilising modular engineered Tregs. Addressing a range of autoimmune and inflammatory diseases as well as preventing rejection in organ transplantation

Welcome to Quell

Quell Therapeutics is a London, UK based, private biopharmaceutical company. Our vision is to be the leading engineered cell therapy company, bringing transformational and valued therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

About Us

Quell was founded in partnership with six world leading experts in the field of immunology from King’s College London, University College London and Hannover Medical School. The Founders have made a significant contribution in the field of Immunology in understanding how to harness the suppressive capacity of Tregs in order to address immune dysfunction by utilising engineered Tregs.

More Info

The Science

Learn more about how we are developing transformational therapies using modular engineered Treg cell therapies for the treatment of a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

More Info

The Pipeline

We are developing therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Learn more about our pipeline of products in development.

More Info

Work With Us

Quell is a culture-led organisation which LIVES its values and we respect the diverse qualities our employees bring. Learn more about working with us.

More Info

Latest News

22/11/22

Quell Therapeutics to Present at Upcoming Investor Conferences in 2022

London, UK and Boston, MA, USA – November 22, 2022 – Quell Therapeutics Ltd (“Quell”), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate…...

Read More
21/11/22

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

Adds significant clinical, translational science and immunology expertise to leadership team as Quell prepares to advance QEL-001 into its first clinical trial and progresses its CAR-Treg cell therapy pipeline programs in Auto-Immunity and Neuro-Inflammation London, UK – November 21, 2022…...

Read More
27/04/22

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Collaboration combines Quell’s pioneering autologous multi-modular Treg cell therapy platform and Cellistic™’s expertise in iPSC cell therapy platform development and scale-upAims to accelerate the development of a next-generation allogeneic Treg platform that could open significant opportunities for Quell’s creation of…...

Read More

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.